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Disclaimers
Research is behind in assessing outcomes for gender diverse individuals.
This talk will be primarily focusing on those who are born biologically female
and can conceive.
My talk is therefore not inclusive of all women.

Let's make this interactive!

Introduction
● Teratogenic medications are commonly prescribed to individuals with
pregnancy potential
● Despite knowledge of potential teratogenic effects, data suggest that
effective communication regarding the risks and benefits of medication
use in the context of the patient’s fertility goals remains inadequate
● We will discuss recommendations for changes in education and
healthcare delivery to facilitate thoughtful prescribing in this population

Learning Objectives
● To review a common scenario faced by primary care physicians caring for
individuals at risk of pregnancy
● To recognize factors that might place certain patients at increased risk of
teratogenic exposure in early pregnancy
● To gain competence in assessing fertility goals in the setting of
medication prescribing

What we will not cover...
● Medication use in patients with a “known” pregnancy
● Safety profiles and risk of birth defects with exposure to ALL medications
prescribed by family medicine physicians
● Options counseling for fetuses exposed to teratogens
● Management of desired pregnancy with exposure to teratogens
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●
●
●
●
●
●
●
●
●

Case Presentation
Background
Definitions & Safety Categories
Commonly Prescribed Teratogenic Medications
Chronic Disease in women with pregnancy potential
“Having the conversation”
Challenges
Recommendations
Summary

Patient Case - 30y/o with Scleroderma
SD, a 30 year old cis-female with PMH significant for Scleroderma presents to your office
hours for a “routine” follow up appointment.
●

Reports being seen recently by her Rheumatologist, who started her on new
medications for her scleroderma

●

She was told to follow up with her PCP because she needs to be on birth control
while on Methotrexate

Patient Case (continued)
●

When asked to clarify, states being prescribed:
○
○
○

Prednisone 20mg daily
Amlodipine 5mg daily
Methotrexate 10mg every week (already received 2 doses)

●

Reported an unsure LMP early in the prior month, and missed period this month

●

Sexually active with male partner, no condom use

Patient Case (continued)
●

In office, Urine preg done and (+)
SENT FOR URGENT ULTRASOUND & LABS
U/S GESTATION:
Fetal
Sac
Crown-Rump
Measurement Yolk Sac
Length
-------------------- -------------------------------10mm
Not visualized Fetal Pole not
(5 0/7wks)
visualized

Heart
Rate
------n/a

Gestational Sac: Seen. Normal position within uterus.

Patient Case (continued)
●
●
●

●

Shortly after US performed, patient called with complaint of “menstrual-like” bleeding
Denied f/c/n/v or severe abd pain
Returned for exam next day:
+ blood pooled in vaginal vault
cervix open w/ bleeding from os
STAT bHCG --> 344 mIU/mL

Dx: Inevitable Abortion
Patient counseled re: miscarriage
Plan: Trend bHCG to 0 to r/o ectopic pregnancy

Patient Case (conclusion)
●
●
●

Reviewed options of all forms of birth control available to the patient.
Pt previously tolerated OCPs (Lutera 0.1/20) without issue and d/c'd last year.
Pt felt confident to manage a daily pill and desires OCPs once current pregnancy is
resolved.

* In review of literature & USMEC, no specific contraindications to initiating hormonal
methods of birth control.
●

Lutera Rx sent to pt pharmacy once bHCG trended to 0

Why did I tell this patient case?
● Teachable moment – missed opportunity!
● Highlights importance of fertility goal assessment and contraceptive
counseling in ALL of our patients with pregnancy potential
● Particularly those with co-morbid illnesses…

Background
● 50% of US pregnancies are unplanned
● Estimated that 3% of births result in a physical or mental defect;
teratogens can increase rates of birth defects
● US women of reproductive age receive ~11.7 million prescriptions for
potentially teratogenic medications each year
● ~6% of US pregnancies occur in women already taking medications with
known teratogenic risk

Background

Background
● Unfortunately, the most significant
adverse effects of medications
occur early in pregnancy (before
pregnancy is diagnosed)

Back to the Case

Back to the Case
There is evidence of significant pregnancy complications with use of
Methotrexate.

Defining Teratogenicity Risk
● FDA has provided a pregnancy risk classification system since 1979
○

Updated in 2015 (we'll discuss in a moment)

● “High-risk” vs “Moderate-risk” teratogens
● Potential teratogenic effects:
○

SAb, malformations, visible developmental impairments, SGA, impaired intellectual
development, carcinogenesis, increased risk of genetic mutations.

● Effects modified by: dose and duration of exposure, gestational age at
time of exposure, etc.

FDA Pregnancy Risk Update --> "Pregnancy
and Lactation Labeling Rule" (PLLR)

FDA Pregnancy Risk Update --> "Pregnancy
and Lactation Labeling Rule" (PLLR)

How has this impacted clinicians?
● Many didn't know the letter

●
●
●

category system was replaced
with a narrative summary (<50%)
Most (68%) felt the summary was
NOT concise
71% found the information helpful
Most (95%) continued to use the
letter system to make prescribing
decisions!

Commonly prescribed medications

Chronic Disease in women with reproductive
potential
● Chronic disease and risk factors affect substantial proportions of
the pregnancies that occur in the US each year
● Clinical Practice Guidelines for preconception care for specific maternal
chronic health conditions have been developed by several national health
professional groups (e.g. ADA, AAN, AHA/ACC)

Chronic Disease in Reproductive Aged
Women

Having the Conversation
●
●
●
●

Fertility Goals
Pregnancy Risk Factors
Contraceptive Options that are safe, effective and reliable
For patients who desire pregnancy:
○

Preconception Counseling of Medication Risk vs Benefit

Nationally, family physicians tend to provide contraceptive counseling more
frequently and are somewhat less likely to prescribe potentially teratogenic
medications than general internists...nonetheless, this still remains a
considerable challenge

Challenges
●
●
●
●

TIME!
Provider’s Contraceptive Knowledge & Comfort Level
Knowledge of teratogens
Continuity of care (or lack thereof)

Challenges (continued)
● Medically complex patients
● Difficulty w/ medication reconciliation (re: meds rx'd by other clinicians)
● Even if prescribed contraception, effectiveness often relies on patient
adherence
○

90% of unintended pregnancies in women using contraception
occur due to inconsistent of incorrect use

Multiple
Prescribing
Clinicians

Teratogenic
Risks?

Not
enough
training

Medically Complex
patient

Not comfortable
discussing
fertility intentions

Not enough
Time

26y/o F presents to office with
palpable, painful breast mass x2
weeks.

Case Vignette

No PMH, no medications
On exam, right lateral chest wall
abscess (~2x3cm)
LMP 20 days ago
Tx: doxycycline and ibuprofen...

RTC one week later
Surrounding cellulitis improved but
still w/ fluctuant mass.

continued...

I&D at bedside; encouraged to
continue doxycycline/ibuprofen,
added short course of tramadol
given pain
Recommend returning in 2 days for
wound check...

2 days later.

continued...

Reports she was seen yesterday at
ER for abdominal pain and
cramping.
+ Preg test, bHCG 169
U/S - no IUP identified
ER Recommended follow bHCG
Now what???

FDA Link: Doxycycline
Approved Drug Label/PLLR

Things to consider
● Many of your menstruating patients
(even those above the age of 50!) may
be at risk of pregnancy
● Routine assessment of pregnancy
potential
● Don’t ignore those EMR medication
alerts!

Recommendations
● Continually assess patients’ fertility intentions & risk factors for pregnancy
● Review teratogenicity risk of medications and avoid high risk medications
if possible
● When prescribing for women desiring pregnancy - if benefit > risk,
prescribe the lowest effective dose of the medication with the most data
on safety in pregnancy
● Always review/reconcile medications
● Review various clinical practice guidelines for preconception care in
chronic disease
● Prevention of Chronic Disease in Women of Reproductive Age! :)

Summary
● Data on teratogenicity is improving, but complex!
● There is a balancing act when prescribing for women of reproductive age
● It is essential that providers understand the safety profile of commonly
used medications and use a systematic approach when prescribing them
● Failure to discuss the risks and benefits may result in inadvertent exposure
to the fetus, and at times, even pregnancy termination

Learning Objectives Reviewed
● To review a common scenario faced by primary care physicians caring for
women of reproductive age
● To recognize factors that might place certain patients at increased risk of
teratogenic exposure in early pregnancy
● To gain competence in assessing fertility goals in the setting of
medication prescribing

Questions?

Resources
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